Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics

Biochemical Pharmacology

Volumn 80, Issue 1, 2010, Pages 122-128

  Shen, Hong Wu ^a   Wu, Chao ^a   Jiang, Xi Ling ^a   Yu, Ai Ming ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 MeO DMT; CYP2D6; MAOI; Pharmacokinetics; Transgenic mouse

Indexed keywords

5 METHOXY N,N DIMETHYLTRYPTAMINE; ALIPHATIC AMINE; AMINE OXIDASE (FLAVIN CONTAINING); BUFOTENINE; BUFURALOL 1' HYDROXYLASE; CYTOCHROME P450 2D6; ENZYME; HARMALINE; INDOLE DERIVATIVE; ISOENZYME; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PSYCHOTROPIC AGENT; RECOMBINANT ENZYME; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEAMINATION; DEMETHYLATION; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME KINETICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; BUFOTENIN; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HALF-LIFE; HARMALINE; HEPATOCYTES; HUMANS; ISOENZYMES; KINETICS; METHOXYDIMETHYLTRYPTAMINES; METHYLATION; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARGYLINE; PHENOTYPE; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS;

EID: 77952293605     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.020     Document Type: Article

References (35)

1. Ott J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 2001, 33(3):273-281.
2. McKenna D.J. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 2004, 102(2):111-129.
3. Yu A.M. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 2008, 10(2):242-253.
4. Aghajanian G.K., Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 1999, 21(2 Suppl.):16S-23S.
5. Tricklebank M.D., Forler C., Middlemiss D.N., Fozard J.R. Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol 1985, 117(1):15-24.
6. Spencer D.G., Glaser T., Traber J. Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine. Psychopharmacology (Berl) 1987, 93(2):158-166.
7. Winter J.C., Filipink R.A., Timineri D., Helsley S.E., Rabin R.A. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacol Biochem Behav 2000, 65(1):75-82.
8. Krebs-Thomson K., Ruiz E.M., Masten V., Buell M., Geyer M.A. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 2006, 189(3):319-329.
9. Brush D.E., Bird S.B., Boyer E.W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol 2004, 42(2):191-195.
10. Sklerov J., Levine B., Moore K.A., King T., Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 2005, 29(8):838-841.
11. DEA-2009-0008. Placement of 5-Methoxy-N,N-Dimethyltryptamine Into Schedule I of the Controlled Substances Act; 2009.
12. Agurell S., Holmstedt B., Lindgren J.E. Metabolism of 5-methoxy-N,-N dimethyltryptamine-14C in the rat. Biochem Pharmacol 1969, 18(10):2771-2781.
13. Roth B.L., Choudhary M.S., Khan N., Uluer A.Z. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 1997, 280(2):576-583.
14. McBride M.C. Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 2000, 32(3):321-331.
15. Yu A.M., Idle J.R., Herraiz T., Kupfer A., Gonzalez F.J. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 2003, 13(6):307-319.
16. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(1):23-37.
17. Yu A.M., Idle J.R., Gonzalez F.J. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004, 36(2):243-277.
18. Wu C., Jiang X.L., Shen H.W., Yu A.M. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 2009, 78(6):617-624.
19. Yu A., Kneller B.M., Rettie A.E., Haining R.L. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 2002, 303(3):1291-1300.
20. Zhang W.Y., Tu Y.B., Haining R.L., Yu A.M. Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6. 27, and CYP2D7 isozymes. Drug Metab Dispos 2009, 37(1):1-4.
21. Jiang X.L., Shen H.W., Yu A.M. Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos 2009, 37(3):443-446.
22. Corchero J., Granvil C.P., Akiyama T.E., Hayhurst G.P., Pimprale S., Feigenbaum L., et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001, 60(6):1260-1267.
23. Shen H.W., Jiang X.L., Yu A.M. Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine: application to pharmacokinetic study. Bioanalysis 2009, 1(1):87-95.
24. Yu A.M., Granvil C.P., Haining R.L., Krausz K.W., Corchero J., Kupfer A., et al. The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ther 2003, 304(2):539-546.
25. de la Torre R., Farre M., Mathuna B.O., Roset P.N., Pizarro N., Segura M., et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol 2005, 61(7):551-554.
26. Kim H., Sablin S.O., Ramsay R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 1997, 337(1):137-142.
27. Ott J. Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs 2001, 33(4):403-407.
28. Halberstadt A.L., Buell M.R., Masten V.L., Risbrough V.B., Geyer M.A. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl) 2008, 201(1):55-66.
29. Kamata T., Katagi M., Kamata H.T., Miki A., Shima N., Zaitsu K., et al. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab Dispos 2006, 34(2):281-287.
30. Narimatsu S., Yonemoto R., Saito K., Takaya K., Kumamoto T., Ishikawa T., et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006, 71(9):1377-1385.
31. Narimatsu S., Yonemoto R., Masuda K., Katsu T., Asanuma M., Kamata T., et al. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2008, 75(3):752-760.
32. Sitaram B.R., McLeod W.R. Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies. Biol Psychiatry 1990, 28(10):841-848.
33. Sitaram B.R., Lockett L., Talomsin R., Blackman G.L., McLeod W.R. In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol 1987, 36(9):1509-1512.
34. Fuller R.W., Snoddy H.D., Perry K.W. Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology 1995, 34(7):799-804.
35. Yu A.M., Idle J.R., Krausz K.W., Kupfer A., Gonzalez F.J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 2003, 305(1):315-322.